Bivamelagon is under clinical development by Rhythm Pharmaceuticals and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate ...
BG-102 is under clinical development by SL Bigen and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) indication ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback